Actigraphy is poor measure of eczema activity

Actigraphy is poor measure of eczema activity
The use of actigraphy to record movement as an objective surrogate for eczema activity is of limited use, according to a study published in the November issue of the British Journal of Dermatology.

(HealthDay)—The use of actigraphy to record movement as an objective surrogate for eczema activity is of limited use, according to a study published in the November issue of the British Journal of Dermatology.

Catriona I. Wootton, M.B., Ch.B., from Queen's Medical Centre in Nottingham, U.K., and colleagues collected accelerometer data from 336 participants in the Softened Water Trial to evaluate its validity as an objective measure of itch assessment in eczema. Data from actigraphy monitors were compared to three standardized scales: Six Area, Six Sign (SASSAD) severity score; Patient Oriented Eczema Measure (POEM); and Family Impact (DFI).

The researchers found that there was poor convergence of the validity of the accelerometer data with the other measures of eczema severity, with a correlation between the actigraphy and SASSAD of 0.15 (P = 0.02) and actigraphy and POEM 0.10 (P = 0.13). The correlation with the DFI was low on assessment for divergent validity against quality-of-life measures. Low, negative correlations were found when comparing the change scores from baseline to week 12 for SASSAD, POEM, and DFI with the change in scores. The meters were generally well tolerated.

"Actigraphy did not correlate well with or quality of life when used as an objective outcome measure in a multicenter clinical trial, and was not responsive to change over time," the authors write. "Further work is needed to establish why this might be, and to establish improved methods of distinguishing between eczema-related and eczema-nonrelated movements."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Topical treatment shows potential for infantile eczema

Aug 08, 2012

(HealthDay) -- Ten days of treatment with a cream containing 15(R/S)-methyl-lipoxin A4 (LXA4) is well tolerated and reduces the severity of infantile eczema, according to a study published online July 26 in the ...

Sequential oral, topical tacrolimus benefits dermatitis

Sep 20, 2012

(HealthDay)—Sequential therapy with oral tacrolimus and topical tacrolimus may be an effective treatment for severe atopic dermatitis (AD), according to a pilot study published in the October issue of the ...

Recommended for you

User comments